Journal article
Signal transduction pathways activated by insulin-like peptide 5 at the relaxin family peptide RXFP4 receptor
SY Ang, DS Hutchinson, N Patil, BA Evans, RAD Bathgate, ML Halls, MA Hossain, RJ Summers, M Kocan
British Journal of Pharmacology | WILEY | Published : 2017
DOI: 10.1111/bph.13522
Abstract
Background and Purpose: Insulin-like peptide 5 (INSL5) is a two-chain, three-disulfide-bonded peptide of the insulin/relaxin superfamily, uniquely expressed in enteroendocrine L-cells of the colon. It is the cognate ligand of relaxin family peptide RXFP4 receptor that is mainly expressed in the colorectum and enteric nervous system. This study identifies new signalling pathways activated by INSL5 acting on RXFP4 receptors. Experimental Approach: INSL5/RXFP4 receptor signalling was investigated using AlphaScreen® proximity assays. Recruitment of Gαi/o proteins by RXFP4 receptors was determined by rescue of Pertussis toxin (PTX)-inhibited cAMP and ERK1/2 responses following transient transfect..
View full abstractGrants
Awarded by Australian National Health and Medical Research Council (NHMRC)
Awarded by NHMRC Career Development Fellowship
Awarded by ARC Linkage grant
Awarded by Australian Research Council
Funding Acknowledgements
This work is supported by an Australian National Health and Medical Research Council (NHMRC) programme grant (1055134; R.J.S.). D.S.H. is supported by an NHMRC Career Development Fellowship (545952). S.Y.A. is supported by a Faculty of Pharmacy and Pharmaceutical Sciences, Monash University Postgraduate Scholarship. Research at the Florey was supported by an ARC Linkage grant to R.A.D.B. and M.A.H. (LP120100654) and by the Victorian Government Operational Infrastructure Support Programme. R.A.D.B. is supported by an NHMRC Research Fellowship.